Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

15    Takeda    $6.6B    down 1.5%
Global revenue*: $17.5B (13th); down 3.3%

R&D spend*: $3.5B (12th), down 5.4%; 20% of rev.

Top brands: Actos ($3.4B); Velcade ($693M), Dexilant ($555M); ActoPlusMet ($472); Amitiza ($264M)

Planned launches: Alogliptin (diab.), TAK-700 (onc.), Contrave (obesity), peginesatide (anemia)

Promotional spend: $668M (11th); 10.1% of rev.

Patent expirations: Actos (2012)

Takeda is in the teeth of a steep patent cliff, with Prevacid bleeding share and Actos, which accounts for half of US sales, set to lose exclusivity in August. The Japanese firm hopes to overcome these headwinds via its “Transformation into a New Takeda” plan, which includes a new R&D hub in Shonan, streamlining the US sales force (by 1,400 US jobs in 2010 and another 700, announced in January) and acquisitions like last year's $13.7-billion deal for European pharma Nycomed and this year's $800-million deal for URL Pharma, while reaching beyond its heritage in metabolic, oncology (Millennium) and CNS to immunology and inflammation. And the company hopes to grow US sales of Prevacid follow-on Dexilant, Daliresp for COPD, Uloric for gout, cancer drug Velcade and antihypertensive Edarbi. Two late-stage candidates, obesity drug Contrave and DPP-4 inhibitor alogliptin, have run into FDA ­roadblocks.
* Global revenue and R&D spend are based on the financial year ending March 31, 2011, the latest data available at press time.

Back to first page

Page 15 of 21
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters